Illumina, Inc. — Q2 2014 Form 10-Q Summary
Business context and reporting period
Illumina develops and sells sequencing and microarray instruments, consumables, services, and related genomic analysis solutions. The filing covers the 13-week quarter and 26-week year-to-date period ended June 29, 2014, compared with periods ended June 30, 2013. The company reports one operating and reportable segment.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | YTD 2014 | YTD 2013 |
|---|---|---|---|---|
| Total revenue | $447.6 million | $346.1 million | $868.3 million | $677.1 million |
| Revenue growth | 29% | — | 28.3% | — |
| Gross profit | $300.5 million | $223.4 million | $578.8 million | $442.7 million |
| Gross margin | 67.1% | 64.6% | 66.7% | 65.4% |
| Income from operations | $100.2 million | $60.0 million | $192.3 million | $14.9 million |
| Net income | $46.6 million | $35.9 million | $106.6 million | $13.3 million |
| Diluted EPS | $0.31 | $0.26 | $0.71 | $0.10 |
Q2 product revenue was $390.8 million, up 25%, while service and other revenue was $56.8 million, up 74%. Q2 consumables revenue increased 15% to $246.7 million and instrument revenue increased 48% to $140.2 million. Growth was driven primarily by sequencing products, including the expanding installed base of HiSeq X Ten and NextSeq platforms; microarray consumables declined.
YTD net cash provided by operating activities was $215.1 million, compared with $176.4 million in the prior-year period. Capital expenditures were $42.3 million. Investing activities used $29.6 million, while financing activities used $222.4 million, principally reflecting debt refinancing, share repurchases, and convertible-note activity. Cash and cash equivalents declined $36.4 million during the first half to $675.2 million.
At June 29, 2014, cash, cash equivalents, and short-term investments totaled approximately $1.1 billion, including $427.8 million of short-term investments. Total debt carrying value was approximately $1.27 billion, consisting primarily of convertible senior notes; $298.0 million was classified as current. Management stated that available liquidity and expected operating cash flow should fund near-term operating and capital needs for at least the next 12 months.
Material changes versus the prior comparable period
- Revenue growth accelerated across sequencing instruments, consumables, and services, with YTD revenue up 28.3%.
- Gross margin increased 130 basis points YTD, primarily because of higher margins on instrument sales.
- YTD operating income improved by $177.5 million, substantially because the prior-year period included a $115.4 million Syntrix legal-contingency charge and $12.3 million of unsolicited tender-offer expenses.
- Research and development expense increased 24% YTD to $160.0 million, and selling, general and administrative expense increased 29% to $224.2 million, reflecting higher headcount, consulting costs, and contributions from 2013 acquisitions.
- In June 2014, Illumina issued $1.15 billion of convertible notes due 2019 and 2021 and used proceeds plus cash on hand to repurchase $600 million principal amount of 2016 Notes for $1.2447 billion. The transaction generated a $31.4 million loss on debt extinguishment.
- The company repurchased $202.4 million of common stock during the first half, with $165.1 million remaining under repurchase authorizations at quarter-end.
Guidance, outlook, commentary, risks, and unusual items
The filing does not provide a clear quantified revenue or earnings forecast. Management expects sequencing market expansion, growth in the installed instrument base, and increasing consumables usage to support future demand. Management also expects operating expenses to continue growing as it invests in product development, commercialization, sales infrastructure, and global business processes.
Key risks include dependence on research and government-related funding, competition and technology changes, successful commercialization and manufacturing execution, integration of acquisitions, foreign-exchange exposure, tax-rate variability, and assumptions used in revenue recognition and other accounting estimates. The company reported no material changes to the risk factors in its 2013 Form 10-K.
Syntrix litigation remains material. Illumina accrued $143.6 million at June 29, 2014, under a judgment involving BeadChip products and an ongoing 8% royalty on specified sales through patent expiration in 2019. The judgment is under appeal; $23.6 million had been deposited with the court for post-judgment royalties, and additional royalties were expected to be deposited during the appeal.
The company’s 2016 Notes, with $320.0 million principal outstanding after the refinancing, were convertible through September 30, 2014. The new 2019 and 2021 Notes were not convertible at quarter-end. No goodwill or significant finite-lived intangible-asset impairment was identified. ASU 2014-09, the new customer-revenue standard, was expected to become effective in fiscal 2017; the company was still evaluating its impact.
Important facts for investors to verify
- Whether sequencing instrument shipments and the installed base convert into sustained consumables revenue growth.
- The effect of rising R&D and SG&A spending on operating leverage and future margins.
- The timing, conversion economics, and cash requirements associated with the 2016, 2019, and 2021 convertible notes.
- The outcome of the Syntrix appeal, ongoing royalty payments, and any exposure beyond the recorded $143.6 million contingency.
- Whether share repurchases and convertible-note dilution materially affect future diluted share count and EPS.
- The eventual accounting impact of ASU 2014-09 and the sustainability of the reported tax rate below the 35% U.S. federal statutory rate.